Ontology highlight
ABSTRACT:
SUBMITTER: Su JM
PROVIDER: S-EPMC4232081 | biostudies-literature | 2014 Dec
REPOSITORIES: biostudies-literature
Su Jack M JM Thompson Patrick P Adesina Adekunle A Li Xiao-Nan XN Kilburn Lindsay L Onar-Thomas Arzu A Kocak Mehmet M Chyla Brenda B McKeegan Evelyn E Warren Katherine E KE Goldman Stewart S Pollack Ian F IF Fouladi Maryam M Chen Alice A Giranda Vincent V Boyett James J Kun Larry L Blaney Susan M SM
Neuro-oncology 20140607 12
<h4>Background</h4>A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) describe the toxicities of this regimen; and (iii) evaluate the plasma pharmacokinetic parameters and extent of PARP inhibition in peripheral blood mononuclear cells (PBMCs) following veliparib. ...[more]